tetano
Editor, Senior Moderator
J Virol. 2013 Mar 20. [Epub ahead of print]
Single Dose Vaccination Of A Recombinant Parainfluenza Virus 5 Expressing NP From H5N1 Provides Broad Immunity Against Influenza A Viruses.
Li Z, Gabbard JD, Mooney A, Gao X, Chen Z, Place RJ, Tompkins SM, He B.
Source
Department of Infectious Diseases, University of Georgia College of Veterinary, Medicine, Athens, GA 30602.
Abstract
Influenza viruses often evade host immunity via antigenic drift and shift despite previous influenza virus infection and/or vaccination. Vaccines that match circulating virus strains are needed for optimal protection. Development of a universal influenza vaccine providing broadly cross-protective immunity will be of great advantage. The nucleoprotein (NP) of influenza A virus is highly conserved among all strains of influenza A viruses and has been explored as an antigen for developing a universal influenza virus vaccine. In this work, we generated a recombinant parainfluenza virus 5 (PIV5) containing NP from H5N1 (A/Vietnam/1203/2004), a highly pathogenic avian influenza (HPAI) virus, between HN and L (PIV5-NP-HN/L) and tested its efficacy. PIV5-NP-HN/L induced humoral and T cell responses in mice. A single inoculation of PIV5-NP-HN/L provided complete protection against lethal heterosubtypic H1N1 challenge, and 50% protection against lethal H5N1 HPAI challenge. To improve efficacy, NP was inserted in different locations within the PIV5 genome. Recombinant PIV5 containing NP between F and SH (PIV5-NP-F/SH) or between SH and HN (PIV5-NP-SH/HN) provided better protection against H5N1 HPAI challenge than PIV5-NP-HN/L. These results suggest that PIV5 expressing the NP from H5N1 has the potential to be utilized as a universal influenza virus vaccine.
PMID:
23514880
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23514880
Single Dose Vaccination Of A Recombinant Parainfluenza Virus 5 Expressing NP From H5N1 Provides Broad Immunity Against Influenza A Viruses.
Li Z, Gabbard JD, Mooney A, Gao X, Chen Z, Place RJ, Tompkins SM, He B.
Source
Department of Infectious Diseases, University of Georgia College of Veterinary, Medicine, Athens, GA 30602.
Abstract
Influenza viruses often evade host immunity via antigenic drift and shift despite previous influenza virus infection and/or vaccination. Vaccines that match circulating virus strains are needed for optimal protection. Development of a universal influenza vaccine providing broadly cross-protective immunity will be of great advantage. The nucleoprotein (NP) of influenza A virus is highly conserved among all strains of influenza A viruses and has been explored as an antigen for developing a universal influenza virus vaccine. In this work, we generated a recombinant parainfluenza virus 5 (PIV5) containing NP from H5N1 (A/Vietnam/1203/2004), a highly pathogenic avian influenza (HPAI) virus, between HN and L (PIV5-NP-HN/L) and tested its efficacy. PIV5-NP-HN/L induced humoral and T cell responses in mice. A single inoculation of PIV5-NP-HN/L provided complete protection against lethal heterosubtypic H1N1 challenge, and 50% protection against lethal H5N1 HPAI challenge. To improve efficacy, NP was inserted in different locations within the PIV5 genome. Recombinant PIV5 containing NP between F and SH (PIV5-NP-F/SH) or between SH and HN (PIV5-NP-SH/HN) provided better protection against H5N1 HPAI challenge than PIV5-NP-HN/L. These results suggest that PIV5 expressing the NP from H5N1 has the potential to be utilized as a universal influenza virus vaccine.
PMID:
23514880
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23514880